An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo

Affiliations

• 1 Department of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
• 2 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
• 3 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• 4 Calibr-Skaggs Institute for Innovative Medicine, La Jolla, CA 92037, USA.
• 5 Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA.
• 6 Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
• 7 Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.
• 8 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• 9 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: sheahan@email.unc.edu.
• 10 Department of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA. Electronic address: sacchett@tamu.edu.